| Supplier |
Creative Peptides |
| Product # |
10-101-86 |
| CAS # |
51952-41-1 |
| Pricing |
Inquire
|
| LabelingTarget |
Gonadotropin-releasing hormone (GNRH) Receptor
|
| Synonyms |
Gonadotropin-releasing hormone; Luteinizing hormone-releasing factor; Fertagyl; Gonadoliberin; Hypocrine; Lutrefact; Relefact; Gonadorelin hydrochloride; Gonadorelin HCl; Factrel; 5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosylglycyl-L-leucyl-L-arginyl-L-prolylglycinamide hydrochloride; L-pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-glycyl-L-leucyl-L-arginyl-L-prolyl-glycinamide hydrochloride
|
| MolecularFormula |
C55H75N17O13
|
| MolecularWeight |
1218.76
|
| Source |
Synthetic
|
| Sequence |
- One Letter Code: XHWSYGLRPG
- Three Letter Code: H-Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2.HCl
|
| Explanation |
Gonadorelin Hydrochloride is a synthetic peptide corresponding to a hypothalamic hormone also known as LHRH or GnRH. As a single dose it stimulates the release of LH and FSH from the anterior pituitary, whereas continuous administration results in downregulation of LH and FSH levels followed by suppression of ovarian and testicular steroid biosynthesis.
|
| ChemicalName |
(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide;hydrochloride
|
| Application |
Gonadorelin hydrochloride stimulates anterior pituitary to release the gonadotropin LH.
|
| Activity |
Agonist
|
| InChI |
InChI=1S/C55H75N17O13.ClH/c1-29(2)19-38(49(80)67-37(9-5-17-60-55(57)58)54(85)72-18-6-10-43(72)53(84)62-25-44(56)75)66-46(77)26-63-47(78)39(20-30-11-13-33(74)14-12-30)68-52(83)42(27-73)71-50(81)40(21-31-23-61-35-8-4-3-7-34(31)35)69-51(82)41(22-32-24-59-28-64-32)70-48(79)36-15-16-45(76)65-36;/h3-4,7-8,11-14,23-24,28-29,36-43,61,73-74H,5-6,9-10,15-22,25-27H2,1-2H3,(H2,56,75)(H,59,64)(H,62,84)(H,63,78)(H,65,76)(H,66,77)(H,67,80)(H,68,83)(H,69,82)(H,70,79)(H,71,81)(H4,57,58,60);1H/t36-,37-,38-,39-,40-,41-,42-,43-;/m0./s1
|
| InChIKey |
UPRWQSQENCASAD-HBBGHHHDSA-N
|
| CanonicalSMILES |
CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)CNC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.Cl
|
| IsomericSMILES |
CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6.Cl
|
| Target |
Gonadotropin-releasing hormone receptor
|
| Reference |
- Recently a patient with severe hypogonadotropic hypogonadism who was given luteinizing hormone-releasing hormone (Factrel) through an infusion pump developed a wheat-and-flare reaction at the sites of injection. Treatment with luteinizing hormone-releasing hormone was discontinued and the immune response was characterized. Skin testing by skin prick test was positive for luteinizing hormone-releasing hormone but negative for vehicle. Radioallergosorbent testing was performed with allergic (patient serum with an elevated serum immunoglobulin E concentration and allergic to inhalant allergens including ragweed pollen) and nonallergic controls. Radioallergosorbent testing was negative for luteinizing hormone-releasing hormone-reactive immunoglobulin E antibodies. Radioimmunoassay of serum of the allergic patient antibody to luteinizing hormone-releasing hormone was positive only for immunoglobulin E. Maximum binding occurred at a dilution of 1:10. Sera from nonallergic and unchallenged patients were negative. It is concluded that this patient developed hypersensitivity reactions caused by IgE antibody to luteinizing hormone-releasing hormone.
- Foster, W. G., Jarrell, J. F., Dolovich, J., & YoungLai, E. V. (1989). Immunoglobulin-mediated hypersensitivity in response to long-term treatment with gonadorelin hydrochloride (Factrel) in a female patient. American journal of obstetrics and gynecology, 160(4), 979-983.
|
| AreasOfInterest |
- Pituitary & Hypothalamic Hormones
- Veterinary Medicine
|
| LongTermStorageConditions |
−20°C
|
| Disease |
- Amenorrhea;
- Diagnostic Test for Gonadotropin Deficiency
|